Key Takeaways
- • Forus (formerly Tandem) raised $160M in Series B funding backed by prominent venture investors including Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC.
- • The company operates an AI-powered network that automates the post-approval treatment pathway, connecting physicians, pharmacies, payers, and biopharmaceutical companies to accelerate patient access to newly approved drugs.
- • Forus addresses a critical inefficiency in drug commercialization: while drug discovery and FDA approval timelines have shortened, the system for getting approved medications to eligible patients remains fragmented and slow, with most promising drugs failing to reach significant patient populations.
- • The platform integrates directly into physician workflows to eliminate administrative friction around insurance authorization, financial assistance, and pharmacy routing, positioning itself as free for both doctors and patients while serving every drug, payer, and pharmacy in the United States.
- • CEO and founder Sahir Jaggi framed the funding as addressing a structural gap between accelerating scientific progress and the inability of legacy healthcare infrastructure to translate innovation into real-world treatment at scale.
Summary
Forus announced a $160M Series B funding round led by a consortium of institutional venture capital firms, positioning the company to scale its AI-powered healthcare infrastructure platform. The round was backed by Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC. The company, which rebranded from its former name Tandem, operates at a critical juncture in pharmaceutical commercialization where scientific acceleration has outpaced the operational systems required to deliver new therapies to patients.
The fundamental problem Forus addresses reflects a persistent market inefficiency in healthcare. While bringing a new drug from development to FDA approval averages 10 to 15 years and costs approximately $2.6 billion, the post-approval infrastructure for connecting eligible patients with approved treatments remains bottlenecked and unreliable. Most promising drugs never reach commercial viability, and those that do reach only a fraction of the patient populations that could clinically benefit. This gap persists despite regulatory approval, indicating a systems-level failure rather than a scientific limitation.
Forus operates as a B2B2C platform embedded within physician workflows, automating all operational steps between clinical prescription and patient treatment initiation. The system handles insurance prior authorization, financial assistance matching, and pharmacy fulfillment routing—eliminating administrative friction that typically delays or prevents treatment access. The platform's architecture supports all drugs, all major payers, and all pharmacies across the United States, positioning it as foundational infrastructure rather than a point solution.
CEO Sahir Jaggi articulated the strategic thesis clearly: while drug discovery velocity has increased, the operational layer converting scientific breakthroughs into patient outcomes has not evolved proportionally. Forus functions as that missing infrastructure layer. By abstracting complexity away from prescribers and patients, the company enables physicians to prescribe with confidence that patients will actually receive treatment, addressing both the supply-side hesitation among clinicians and the real-world access barriers patients face. The company operates on a free model for both physicians and patients, suggesting a B2B revenue model targeting payers and biopharmaceutical companies seeking to optimize market access and patient outcomes.
The institutional investor backing reflects confidence in both the market opportunity and the team's ability to execute a complex platform connecting fragmented healthcare stakeholders. For alternative investors with exposure to healthcare infrastructure and digital health, Forus represents an early-stage bet on a structural healthcare inefficiency expected to command significant capital and consolidation over the next 5 to 10 years.
The fundamental problem Forus addresses reflects a persistent market inefficiency in healthcare. While bringing a new drug from development to FDA approval averages 10 to 15 years and costs approximately $2.6 billion, the post-approval infrastructure for connecting eligible patients with approved treatments remains bottlenecked and unreliable. Most promising drugs never reach commercial viability, and those that do reach only a fraction of the patient populations that could clinically benefit. This gap persists despite regulatory approval, indicating a systems-level failure rather than a scientific limitation.
Forus operates as a B2B2C platform embedded within physician workflows, automating all operational steps between clinical prescription and patient treatment initiation. The system handles insurance prior authorization, financial assistance matching, and pharmacy fulfillment routing—eliminating administrative friction that typically delays or prevents treatment access. The platform's architecture supports all drugs, all major payers, and all pharmacies across the United States, positioning it as foundational infrastructure rather than a point solution.
CEO Sahir Jaggi articulated the strategic thesis clearly: while drug discovery velocity has increased, the operational layer converting scientific breakthroughs into patient outcomes has not evolved proportionally. Forus functions as that missing infrastructure layer. By abstracting complexity away from prescribers and patients, the company enables physicians to prescribe with confidence that patients will actually receive treatment, addressing both the supply-side hesitation among clinicians and the real-world access barriers patients face. The company operates on a free model for both physicians and patients, suggesting a B2B revenue model targeting payers and biopharmaceutical companies seeking to optimize market access and patient outcomes.
The institutional investor backing reflects confidence in both the market opportunity and the team's ability to execute a complex platform connecting fragmented healthcare stakeholders. For alternative investors with exposure to healthcare infrastructure and digital health, Forus represents an early-stage bet on a structural healthcare inefficiency expected to command significant capital and consolidation over the next 5 to 10 years.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.